Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Orbray Co. Ltd. currently manages 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 2 distinct examiners and 2 distinct art units. This distribution indicates a broader technical or administrative footprint compared to portfolios where all matters are concentrated under a single point of contact. The use of 2 distinct art units suggests that the company's innovations may span different sub-specialties within the broader biotechnology sector.
The busiest examiner for the company is MARTIN, PAUL C, who is responsible for 1 busiest examiner pending office action. This examiner handles a portion of the company's total 2 pending office actions. The remaining pending action is managed by the other of the 2 distinct examiners, requiring the company to navigate multiple examiner preferences simultaneously. This split workload means that the prosecution strategy cannot be entirely centralized, as each examiner may have different interpretations of the prior art or procedural requirements.
With 2 pending office actions in total, the portfolio is in a state of active review across multiple channels. The presence of 2 distinct examiners provides the company with different perspectives on their patent applications. Practitioners should monitor the progress of the 1 busiest examiner pending office action under MARTIN, PAUL C while also addressing the requirements of the second examiner to ensure consistent results across the Biotechnology & Pharmaceuticals technology area.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §102 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MARTIN, PAUL C | 1 | 41.8% | +21.6% |
| SAUNDERS, MATTHEW P | 1 | 47.0% | +38.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17805592 | METHOD FOR COLLECTING LIVING TISSUE | MARTIN, PAUL C | 14d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17805592 | METHOD FOR COLLECTING LIVING TISSUE | MARTIN, PAUL C | 14d |
| 17647550 | DENTAL IMPLANT BODY AND METHOD FOR MANUFACTURING DENTAL IMPLANT BODY | SAUNDERS, MATTHEW P | 39d |
| Art Unit | Apps |
|---|---|
| 1653 | 1 |
| 3772 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17805592 | METHOD FOR COLLECTING LIVING TISSUE | MARTIN, PAUL C | 1653 | §103§112 | Final Rejection | 14d | Pending | Jun 06, 2022 |
| 17647550 | DENTAL IMPLANT BODY AND METHOD FOR MANUFACTURING DENTAL IMPLANT BODY | SAUNDERS, MATTHEW P | 3772 | §102 | Non-Final OA | 39d | Pending | Jan 10, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial